Is Finch Therapeutics Group, Inc. overvalued or undervalued?
As of October 5, 2023, Finch Therapeutics Group, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 3.8, significantly exceeding those of its peers, indicating that investors are paying a premium without sufficient justification.
As of 5 October 2023, Finch Therapeutics Group, Inc. has moved from fair to overvalued. The company currently shows a price-to-earnings ratio of 45.2, a price-to-book ratio of 3.8, and a debt-to-equity ratio of 1.5. Compared to its peers, such as Seres Therapeutics with a price-to-earnings ratio of 12.5 and 4D Molecular Therapeutics with a price-to-book ratio of 2.1, Finch appears to be trading at a significant premium.Given these metrics, Finch Therapeutics is considered overvalued. The elevated ratios indicate that investors are paying more for each dollar of earnings and book value compared to its peers, suggesting a lack of justification for its current market price. Additionally, while the stock has shown a positive return recently, it still does not align with the overall valuation metrics when compared to its industry counterparts.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
